Patents by Inventor Florence Lebon

Florence Lebon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses
    Patent number: 7863450
    Abstract: The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, (I), wherein A1 is CH C(CH3) or N; R1 is hydrogen or halogen; R2 is (II); A2 is O or S; R3 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy; R4 is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl or —O—(CH2)n-NR12aR each CH2 in —O—(CH2)n-NR12aR12b being optionally substituted by one or two C1-4 alkyl; R5 is hydrogen or —O—(CH2)m—NR13aR13b, each CH2 in —O—(CH2)m—NR13aR13b being optionally substituted by one or two C1-4 alkyl, and at least one of R4 and R5 should be a —O—(CH2)n-NR12/13aR12/13b group.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: January 4, 2011
    Assignee: UCB Pharma, S.A.
    Inventors: Sylvain Celanire, Patrice Talaga, Regorius Leurs, Frederic Denonne, Henkdrik Timmerman, Florence Lebon
  • Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses
    Publication number: 20080161331
    Abstract: The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, (I), wherein A1 is CH C(CH3) or N; R1 is hydrogen or halogen; R2 is (II); A2 is O or S; R3 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy; R4 is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl or —O—(CH2)n-NR12aR each CH2 in —O—(CH2)n-NR12aR 12b being optionally substituted by one or two C1-4 alkyl; R5 is hydrogen or —O—(CH2)m—NR13aR13b, each CH2 in —O—(CH2)m—NR13aR13b being optionally substituted by one or two C1-4 alkyl, and at least one of R4 and R5 should be a —O—(CH2)n-NR12/13aR12/13b group.
    Type: Application
    Filed: March 29, 2006
    Publication date: July 3, 2008
    Applicant: UCB PHARMA, S.A.
    Inventors: Regorius Leurs, Henkdrik Timmerman, Sylvain Celanire, Patrice Talaga, Frederic Denonne, Florence Lebon